naproxen has been researched along with probenecid in 23 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (probenecid) | Trials (probenecid) | Recent Studies (post-2010) (probenecid) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 3,664 | 292 | 375 |
| Protein | Taxonomy | naproxen (IC50) | probenecid (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 8 | Mus musculus (house mouse) | 3.02 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 6.85 | |
| Solute carrier family 22 member 8 | Homo sapiens (human) | 6.965 | |
| Solute carrier family 22 member 8 | Rattus norvegicus (Norway rat) | 6.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Cihlar, T; Ho, ES; Mulato, AS | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Emmerson, BT | 1 |
| Chaplin, M; Mroszczak, E; Runkel, R; Segre, E; Sevelius, H | 1 |
| Bidault, R; Haumont, M; Herber, R; Magdalou, J; Siest, G; van Es, H | 1 |
| Buskin, JN; Holford, NH; Riegelman, S; Upton, RA; Williams, RL | 1 |
| Iley, J; Mendes, E; Moreira, R; Souza, S | 1 |
| Balchen, M; Gjelstad, A; Pedersen-Bjergaard, S; Rasmussen, KE | 1 |
| Jung, JA; Parvez, MM; Shin, HJ; Shin, JG | 1 |
4 review(s) available for naproxen and probenecid
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug control of gout and hyperuricaemia.
Topics: Allopurinol; Arthritis; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Naproxen; Phenylbutazone; Probenecid; Sulfinpyrazone; Uric Acid; Uricosuric Agents | 1978 |
19 other study(ies) available for naproxen and probenecid
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
Topics: Adenine; Anion Transport Proteins; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biological Transport; Carrier Proteins; Humans; Kidney; Organophosphonates; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Naproxen-probenecid interaction.
Topics: Adult; Drug Interactions; Humans; Kidney; Kinetics; Male; Naproxen; Probenecid | 1978 |
Glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Estrone; Ethinyl Estradiol; Flurbiprofen; Glucuronosyltransferase; Humans; Microsomes, Liver; Naproxen; Phenylpropionates; Probenecid; Testosterone; Zidovudine | 1992 |
Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.
Topics: Humans; Hydrolysis; Ketoprofen; Male; Naproxen; Phenylpropionates; Probenecid; Specimen Handling; Time Factors | 1980 |
Cleavage of tertiary amidomethyl ester prodrugs of carboxylic acids by rat liver homogenates.
Topics: Amides; Animals; Benzoic Acid; Carboxylic Acids; Clofibric Acid; Diclofenac; Drug Interactions; Esters; Hydrolases; Hydrolysis; Ibuprofen; In Vitro Techniques; Liver; Male; Naproxen; Physostigmine; Proadifen; Probenecid; Prodrugs; Rats; Rats, Sprague-Dawley; Refractometry; Solubility; Structure-Activity Relationship; Time Factors; Valproic Acid | 1999 |
Electrokinetic migration of acidic drugs across a supported liquid membrane.
Topics: Acids; Chromatography, Micellar Electrokinetic Capillary; Electrophoresis, Capillary; Flurbiprofen; Gemfibrozil; Heptanol; Hydrogen-Ion Concentration; Ketoprofen; Membranes, Artificial; Naproxen; Pharmaceutical Preparations; Probenecid; Reproducibility of Results; Warfarin | 2007 |
Evaluation of
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cimetidine; Drug Interactions; HEK293 Cells; Humans; Ibuprofen; Liver-Specific Organic Anion Transporter 1; Naproxen; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 2; Probenecid; Proton Pump Inhibitors; Quinidine; Rifampin; Verapamil | 2017 |